Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

The New England Journal of Medicine
Rachel B JonesEuropean Vasculitis Study Group

Abstract

Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vasculitis. We randomly assigned, in a 3:1 ratio, 44 patients with newly diagnosed ANCA-associated vasculitis and renal involvement to a standard glucocorticoid regimen plus either rituximab at a dose of 375 mg per square meter of body-surface area per week for 4 weeks, with two intravenous cyclophosphamide pulses (33 patients, the rituximab group), or intravenous cyclophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group). Primary end points were sustained remission rates at 12 months and severe adverse events. The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a...Continue Reading

References

Aug 2, 1979·The New England Journal of Medicine·A S FauciS M Wolff
Feb 1, 1994·Arthritis and Rheumatism·J C JennetteC G Kallenberg
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
May 18, 1999·The Journal of Allergy and Clinical Immunology·E R PopaJ W Tervaert
Nov 10, 2001·BMJ : British Medical Journal·A J Vickers, D G Altman
Apr 1, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Anthony D BoothUNKNOWN Pan-Thames Renal Research Group
Jul 4, 2003·The New England Journal of Medicine·David JayneUNKNOWN European Vasculitis Study Group
Jun 18, 2004·The New England Journal of Medicine·Jonathan C W EdwardsTim Shaw
Oct 15, 2005·American Journal of Respiratory and Critical Care Medicine·Karina A KeoghUlrich Specks
Oct 26, 2005·Journal of Autoimmunity·Markus KrumbholzEdgar Meinl
Apr 21, 2006·Journal of the American Society of Nephrology : JASN·J Charles JennetteRonald J Falk
Jun 22, 2007·Journal of the American Society of Nephrology : JASN·David R W JayneUNKNOWN European Vasculitis Study Group
Sep 7, 2007·Rheumatology·C LapraikUNKNOWN BSR and BHPR Standards, Guidelines and Audit Working Group
Apr 17, 2008·Annals of the Rheumatic Diseases·C MukhtyarUNKNOWN European Vasculitis Study Group
Sep 19, 2008·Journal of the American Society of Nephrology : JASN·David Jayne
Dec 5, 2008·Annals of the Rheumatic Diseases·C MukhtyarR A Luqmani
May 20, 2009·Annals of Internal Medicine·Kirsten de GrootUNKNOWN EUVAS (European Vasculitis Study Group)
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group

❮ Previous
Next ❯

Citations

Jul 23, 2011·Zeitschrift für Rheumatologie·E Reinhold-Keller, F Moosig
Jun 16, 2012·Zeitschrift für Rheumatologie·M Janneck, C Iking-Konert
Jun 16, 2012·Zeitschrift für Rheumatologie·J O SchröderM Both
Nov 10, 2012·Zeitschrift für Rheumatologie·J U HolleW L Gross
Apr 24, 2013·Zeitschrift für Rheumatologie·H Morbach, H J Girschick
Nov 7, 2013·Zeitschrift für Rheumatologie·I Kötter, J C Henes
Oct 25, 2013·Journal of Neurology·Matthew Evans, Hadi Manji
Sep 21, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Kjell Tullus, Stephen D Marks
Nov 6, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Michal MalinaClaus Peter Schmitt
Dec 15, 2010·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·Sanjeev BawejaLawrence P McMahon
Apr 28, 2011·Clinical Rheumatology·Frances ReesPeter Lanyon
May 8, 2013·Clinical Rheumatology·Mislav RadicJosipa Radic
Nov 1, 2011·Modern Rheumatology·Chethana Dharmapalaiah, Richard A Watts
Nov 2, 2011·Internal and Emergency Medicine·Mariagrazia CatanosoCarlo Salvarani
Oct 12, 2012·Current Allergy and Asthma Reports·Jennifer L RogersTeresa K Tarrant
Oct 29, 2013·Current Pain and Headache Reports·Noa SchwartzJohannes Nowatzky
Sep 30, 2010·Current Rheumatology Reports·Cees G M Kallenberg
Aug 17, 2012·Current Rheumatology Reports·Duvuru Geetha, Philip Seo
Jan 25, 2012·Current Treatment Options in Cardiovascular Medicine·Carol A Langford
Feb 22, 2011·Clinical Reviews in Allergy & Immunology·Cees G M Kallenberg
Jun 7, 2012·Clinical Reviews in Allergy & Immunology·Cees G M Kallenberg
Mar 20, 2013·Best Practice & Research. Clinical Rheumatology·Rosemary WallerRaashid Luqmani
Mar 20, 2013·Best Practice & Research. Clinical Rheumatology·Gunnar Tomasson
Mar 20, 2013·Best Practice & Research. Clinical Rheumatology·Loïc Guillevin
Mar 14, 2013·The Journal of Laryngology and Otology·A K Ebrahim, J W Loock
Dec 22, 2010·Nature Reviews. Nephrology·Ulf Schönermarck, Kirsten de Groot
Mar 23, 2011·Nature Reviews. Nephrology·Ruth M Tarzi, Charles D Pusey
Jun 6, 2012·Nature Reviews. Nephrology·Nadezhda Wall, Lorraine Harper
Feb 9, 2012·Nature Reviews. Nephrology·JulieAnne G McGregor, Ronald J Falk
Oct 2, 2013·Nature Reviews. Nephrology·Ruth Tarzi, Charles Pusey
Nov 6, 2013·Nature Reviews. Nephrology·Ulf SchönermarckKirsten de Groot
Oct 7, 2010·Nature Reviews. Rheumatology·Min Chen, Cees G M Kallenberg
Sep 1, 2011·Nature Reviews. Rheumatology·Julia U Holle, Wolfgang L Gross
Mar 10, 2011·Nature Reviews. Rheumatology·Ronald F van Vollenhoven
Nov 14, 2012·Nature Reviews. Rheumatology·Raashid Luqmani
Jul 22, 2010·The New England Journal of Medicine·Ronald J Falk, J Charles Jennette
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group
Jul 20, 2012·The New England Journal of Medicine·Paul A LyonsKenneth G C Smith
Aug 2, 2013·The New England Journal of Medicine·Ulrich SpecksUNKNOWN RAVE-ITN Research Group
Feb 18, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Rodrigo Cartin-CebaFernando C Fervenza
Mar 19, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nicholas MansfieldAlan D Salama
Sep 13, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jan Willem Cohen Tervaert
Feb 5, 2011·Rheumatology·Eleana NtatsakiRichard A Watts

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
John H StoneRAVE-ITN Research Group
Journal of the American Society of Nephrology : JASN
David R W JayneEuropean Vasculitis Study Group
The New England Journal of Medicine
C PagnouxFrench Vasculitis Study Group
© 2021 Meta ULC. All rights reserved